The results of our study did not confirm significant differences in the classification into risk groups and the response to remission-inducing treatment, or achieving remission after the end of the first-line treatment between the groups of patients with CD34+CD38+ and CD34+CD38− lymphoblasts assessed at the diagnosis of BCP-ALL. The gene discussed is CD34; the disease is acute lymphoblastic leukemia.